April 24, 2013
Dr. Miguel Forte will present at the 19th ISCT Annual Meeting
"One year multiple injections of antigen specific T regulatory lymphocytes in refractory Crohn's disease patients, extension of CATS1 study"
P. Desreumaux et all.
Treg: Regulatory T Cells and T Helper Cells
Our proprietary technology platform represents a novel potential treatment option for a wide range of chronic inflammatory diseases.
We are focusing on chronic inflammatory diseases where current treatments show limited efficacy, limited tolerability and for which 30% of the patients treated develop resistance.
Inflammatory Bowel Disease, primarily treatment resistant Crohn’s Disease
Ovasave® is our lead product candidate. The first in man, open label, phase I/II clinical trial for severe refractory Crohn's Disease patients has been completed (link1) (link2) and showed good tolerability and a strong efficacy signal in the best dose group. A phase IIb placebo controlled study is planned in the same patient population.